# Global Blood Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/global-blood-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.globalbloodtx.com
- Total disclosed funding: $89M
- Latest round: Series B (Dec 22, 2014)
- Investors on record: 6

## About

Global Blood Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for sickle cell disease and other serious blood disorders, striving to improve the lives of patients worldwide.Founded in 2012, Global Blood Therapeutics, Inc. is headquartered in San Francisco, US. The company specializes in developing therapies for blood disorders and has undergone significant funding rounds, including a TRADE SALE to Pfizer Inc. in October 2022 for USD 5.4 bn. The company, led by Brian Metcalf, Jorge H, and Ted Love, successfully raised USD 120 mn in an IPO in August 2015 and USD 121.2 mn in a private placement in June 2016.Global Blood Therapeutics specializes in the development and commercialization of therapies for sickle cell disease and other serious blood disorders. Its flagship product, voxelotor, received FDA approval in November 2019 and is designed to increase hemoglobin levels in patients with sickle cell disease, thereby reducing painful vaso-occlusive crises. The company targets healthcare providers, hospitals, and specialty pharmacies globally, ensuring patients have access to their products.In the most recent year, 2021, Global Blood Therapeutics reported revenue of USD 194.75 mn and an EBITDA of USD 296.51 mn, primarily generated through the sale of voxelotor via pharmacies and healthcare providers. The company's revenue model emphasizes direct engagement with patients and clinicians, facilitating effective treatment outcomes.To support future growth, Global Blood Therapeutics plans to utilize the funding from its most recent TRADE SALE to Pfizer Inc. to accelerate its lead drug candidate, GBT440, for the treatment of sickle cell disease. The company aims to explore new markets and geographic regions, focusing on expanding its presence in Europe and other international markets by late 2023.

## Funding rounds

- Series B, Dec 22, 2014, $48M — Wellington Management, Deerfield Management, RA Capital Management, Sabby Capital, Perceptive Advisors
- Series A, May 31, 2012, $41M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B